共 50 条
- [1] ROLE OF 18 F-FDG PET/CT IN THE ASSESSMENT OF PATIENTS WITH SMOLDERING MULTIPLE MYELOMAHAEMATOLOGICA, 2013, 98 : 596 - 596Za, T.Rossi, E.Caldarella, C.Ciminello, A.Betti, S.Fianchi, L.Rufini, V.Leone, G.Giordano, A.De Stefano, V.
- [2] Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd MaintenanceJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (27)Mateos, Maria-VictoriaMartinez-Lopez, JoaquinRodriguez Otero, PaulaGonzalez-Calle, VeronicaGonzalez, Marta SoniaOriol, AlbertGutierrez, Norma C.Rios-Tamayo, RafaelRosinol, LauraAlvarez Rivas, Miguel AngelBargay, JoanGonzalez-Rodriguez, Ana PilarAlegre, AdrianEscalante, FernandoInigo Rodriguez, Maria Belende la Rubia, JavierTeruel, Ana Isabelde Arriba, FelipePalomera, LuisHernandez, Miguel T.Lopez Jimenez, JavierReinoso-Segura, MartaGarcia Mateo, AranzazuOcio, Enrique M.Paiva, BrunoPuig, NoemiCedena, M. TeresaBlade, JoanLahuerta, Juan JoseSan-Miguel, Jesus F.
- [3] 18F-FDG-PET/CT in the evaluation of response to treatment in patients with active multiple myelomaEUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S379 - S379Eftychiou, N. S.Fuster, D.Setoain, X.Rosinol, L.Perissinotti, A.Depetris, M.Blade, J.Pons, F.
- [4] Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Therapy in High-Risk Newly Diagnosed Multiple MyelomaBLOOD, 2023, 142Tan, CarlynKorde, NehaDerkach, AndriyHultcrantz, MalinMaclachlan, Kylee H.Hassoun, HaniMailankody, ShamShah, Urvi A.Rajeeve, SrideviPatel, DhwaniLesokhin, AlexanderLahoud, Oscar BoutrosShah, Gunjan L.Scordo, MichaelChung, DavidLandau, HeatherGiralt, Sergio A.Hofmeister, Craig C.Kaufman, Jonathan L.Nooka, Ajay K.Usmani, Saad Z.Lonial, SagarJoseph, Nisha S.
- [5] Multiple Myeloma: 18F-FDG-PET/CT and Diagnostic ImagingSEMINARS IN NUCLEAR MEDICINE, 2015, 45 (01) : 16 - 31Mihailovic, JasnaGoldsmith, Stanley J.
- [6] Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative StudyBLOOD, 2020, 136Kazandjian, DickranHill, ElizabethMorrison, CandisDew, AlexanderKorde, NehaMailankody, ShamManasanch, Elisabet E.Kwok, Mary L.Bhutani, ManishaTageja, NishantZhang, YongCarpenter, AshleyEpstein, MonicaEmanuel, MichaelLu, CrystalBraylan, Raul C.Calvo, Katherine R.Choyke, PeterDulau-Florea, AlinaMena, EstherLindenberg, LizaMaric, IrinaPatel, NishaStetler-Stevenson, MaryaliceWang, Hao-WeiYuan, Constance M.Steinberg, Seth M.Figg, William D.Roschewski, MarkLandgren, Ola
- [7] Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction Therapy in Newly Diagnosed High-Risk Multiple MyelomaBLOOD, 2022, 140 : 1817 - 1819Tan, CarlynNemirovsky, DavidDerkach, AndriyHultcrantz, MalinHassoun, HaniMailankody, ShamShah, Urvi A.Patel, DhwaniMaclachlan, Kylee H.Lahoud, Oscar B.Shah, Gunjan L.Scordo, MichaelChung, David J.Landau, HeatherGiralt, Sergio A.Lesokhin, Alexander M.Korde, NehaUsmani, Saad
- [8] The Role of 18F-FDG-PET/CT Imaging in Predicting Outcome of Patients with Newly Diagnosed Multiple MyelomaJOURNAL OF NUCLEAR MEDICINE, 2021, 62Mena, EstherLindenberg, Maria LizaTurkbey, IsmailAdler, StephenEclarinal, PhilipMcKinney, YolandaWeaver, JuanitaChoyke, PeterKazandjian, Dickran
- [9] 18F-FDG-PET/CT and Osteolytic Bone Disease in Multiple MyelomaBLOOD, 2016, 128 (22)Ostergaard, BrianMortensen, Julie R.Nielsen, Anne L.Asmussen, Jon T.Gerke, OkePlesner, TorbenHoilund-Carlsen, Poul FlemmingAbildgaard, Niels
- [10] Correlation of histopathological and 18F-FDG-PET/CT data in patients with symptomatic multiple myelomaEUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S473 - S473Turk, M.Sachpekidis, C.Sauer, S.Hillengass, J.Dimitrakopoulou-Strauss, A.